Research analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
Aptevo Therapeutics stock opened at $2.44 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.16 and a current ratio of 3.16. Aptevo Therapeutics has a one year low of $1.94 and a one year high of $7.55. The business has a 50 day simple moving average of $2.62 and a 200 day simple moving average of $3.21.
Aptevo Therapeutics (NASDAQ:APVO – Get Rating) last posted its earnings results on Thursday, November 10th. The biotechnology company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.11. Research analysts anticipate that Aptevo Therapeutics will post -6.58 EPS for the current fiscal year.
Hedge Funds Weigh In On Aptevo Therapeutics
Aptevo Therapeutics Company Profile
Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.
- Get a free copy of the StockNews.com research report on Aptevo Therapeutics (APVO)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.